Further assessment of the molecular differences between EWSR1-NFATc2 and other EWSR1 fusion positive sarcomas may shed light on the disparity of response to chemotherapeutics while providing insight into new treatment methods for these patients. The gene discussed is NFATC2; the disease is sarcoma.